Company description

ProJect Pharmaceutics, based in Martinsried/Munich, Germany, transforms proteins, peptides and

delicate small molecules into pioneering drugs. ProJect Pharmaceutics adds value to client’s bio-
pharmaceutical products by applying an innovative concept of development called Advaceutics.

Based on the Advaceutics concept, ProJect Pharmaceutics designs optimized formulations and
delivery systems for biologics that are stable, convenient and safe. Tailored to these optimized
systems the company develops cost-effective manufacturing processes and transfers those from its
own pilot labs to large-scale manufacturing. ProJect Pharmaceutics makes sure that investigational
products, biosimilars as well as “bio-betters” are developed effectively and will run smoothly in
clinical and commercial scale GMP manufacturing.

ProJect Pharmaceutics was founded and is managed by Andreas Schütz and Klaus Hellerbrand, two
leading experts in protein formulation and pharmaceutical process development with many years of
experience in bio-pharmaceutics. Their combined expertise and complementary set of qualifications
enables ProJect Pharmaceutics to deliver the high-tech pharmaceutical services that are in increased
demand for the global biopharmaceutical industry.

Products and services

predictive formulation analytics, formulation development, lyophilization process development and
optimization, lyophilization in dual chamber prefilled syringe, development of liposomal
formulations, producible by simple stirring, manufacturing of preclinical study material, technology-
transfer including scale-up to GMP-manufacturer